UK markets closed

Invitae Corporation (0JDB.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
0.0002-0.0003 (-60.00%)
At close: 03:47PM BST
Full screen
Previous close0.0005
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.0002 - 0.0002
52-week range0.0002 - 1.6596
Avg. volume225,013
Market cap182
Beta (5Y monthly)1.28
PE ratio (TTM)N/A
EPS (TTM)-2.0560
Earnings date07 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process

    Invitae (OTC: NVTA), a leading medical genetics company, announced today that it is building on previous actions to manage costs and improve its business structure by filing for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of New Jersey. Through this filing, the Company intends to safeguard its business, customers, patients and employees while working to execute an efficient and value-maximizing sale process with the support of its senior noteholders.

  • Benzinga

    SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy

    Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics company, grappling with a substantial $1.5 billion debt burden, is enlisting the expertise of restructuring advisers from FTI Consulting and legal counsel from Kirkland & Ellis to navigate its financial challenges. Amidst this financial turmoil, Invitae is actively exploring various strategic options,

  • PR Newswire

    Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

    Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, designed to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs.